Institutional analysts are intensifying their scrutiny of Figma and DaVita as both companies navigate pivotal transitions in the SaaS and healthcare sectors. While Figma solidifies its post-IPO independence through AI-driven design tools, DaVita is increasingly leveraging cloud-based predictive analytics to maintain its dominance in the dialysis market.
Figma enters its Q4 2025 reporting period under intense scrutiny as it seeks to prove its independent valuation following the collapsed Adobe merger. Analysts are focused on the company's ability to convert its AI-driven Dev Mode features into sustained ARR growth amidst a tightening SaaS spending environment.
About Figma, Inc. coverage
This page surfaces every story mentioning Figma, Inc. across our saas coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running saas beat. Cross-entity comparisons live on our compare view.
What you see
What it tells you
Story count
Number of distinct stories where Figma, Inc. was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.